Lupus nephritis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Lupus nephritis Classification and external resources | |
 | |
|---|---|
| Type IV lupus nephritis: The classic "flea-bitten" appearance of the cortical surface in the diffuse proliferative glomerulonephritides. (Courtesy of Ed Uthman, MD)]] | |
| ICD-10 | N08.5 |
| ICD-9 | 583.81 |
| MedlinePlus | 000481 |
| eMedicine | med/1597 |
| MeSH | D008181 |
|
WikiDoc Resources for Lupus nephritis | |
|
Articles | |
|---|---|
|
Most recent articles on Lupus nephritis Most cited articles on Lupus nephritis | |
|
Media | |
|
Powerpoint slides on Lupus nephritis | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Lupus nephritis at Clinical Trials.gov Trial results on Lupus nephritis Clinical Trials on Lupus nephritis at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Lupus nephritis NICE Guidance on Lupus nephritis
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Lupus nephritis Discussion groups on Lupus nephritis Patient Handouts on Lupus nephritis Directions to Hospitals Treating Lupus nephritis Risk calculators and risk factors for Lupus nephritis
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Lupus nephritis | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Phone:617-525-7431
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Lupus nephritis is an inflammation of the kidney caused by systemic lupus erythematosus (SLE), a disease of the immune system. Apart from the kidneys, SLE can also damage the skin, joints, nervous system and virtually any organ or system in the body.
Signs and symptoms
Sufferers of lupus nephritis may or may not have symptoms of kidney disease, but it can manifest itself through weight gain, high blood pressure, darker foamy urine or swelling around the eyes, legs, ankles or fingers.
Furthermore, patients may suffer from other symptoms of lupus unrelated to kidney function. Such symptoms can include arthritis, fevers, gastro-intenstinal disturbances, headaches, fatigue, and fluid in the joints.
Diagnosis
The diagnosis of lupus nephritis depends on blood tests, urinalysis, X-rays, ultrasound scans of the kidneys, and a kidney biopsy. The World Health Organization has divided lupus nephritis into five classes based on the biopsy.
- Class I is histologically normal and does not show any evidence of disease.
- Class II is based on a finding of mesangial lupus nephritis. This form typically responds completely to treatment with corticosteroids.
- Class III is focal proliferative nephritis and often successfully responds to treatment with high doses of corticosteroids.
- Class IV is diffuse proliferative nephritis. This form is mainly treated with corticosteroids and immunosuppressant drugs.
- Class V is membranous nephritis and is characterized by extreme edema and protein loss.
- Class VI Glomerulosclerosis
Medicines which decrease swelling, lower blood pressure and decrease inflammation by suppressing the immune system. Patients may need to monitor intake of protein, sodium, and potassium. Patients with severe disease should restrict their sodium intake to 2 grams per day and limit fluid as well. Depending on the histology, renal function and degree of proteinuria, patients may require steroid therapy or chemotherapy regimens such as cyclophosphamide, azathioprine, mycophenolate mofetil or cyclosporine.
The medical therapy for lupus nephritis depends on the severity of the disease. For mild disease, corticosteroids are generally prescribed. More severe disease requires treatment with immunosuppressant agents. The two most commonly used agents are mycophenolate mofetil and intravenous cyclophosphamide. One recent study compared these two drugs.[1] The authors showed that patients with Class III or IV disease are more likely to benefit from mycophenolate mofetil as compared to cyclophosphamide. As a result, mycophenolate mofetil is now considered to be the first-line therapy for this disease.
References
External links
- Lupus Nephritis Clinical Research Study
- London Lupus Centre - Treatment, Diagnosis, Research
- Lupus Foundation of America, Inc.
- Lupus Research Institute
- S.L.E. Lupus Foundation
- Lupus International
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
